

WAY
16

Dexcom G7 is the Most Accurate, Simple, and Most Affordable* CGM, Leading to Lasting Adherence for Patients^{1,2}

Dexcom G7 is the most accurate continuous glucose monitoring (CGM) system¹ that leads to proven results.³⁻⁷ As the most covered CGM brand,⁸ Dexcom offers affordable care without compromising quality for the broadest audience of people with diabetes.

President & CEO: Kevin R. Sayer
Founded: 1999
Employees: >8,000 globally
Stock Symbol: DXCM
Toll-Free Phone: (888) 738-3646
Website: Dexcom.com

Dexcom

Company Background

Dexcom, Inc. empowers people to take control of health through innovative CGM systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Product Overview

Dexcom G7 is the next-generation CGM system for patients with all types of diabetes and treatments, so they can more confidently manage it each day. Dexcom G7 is the simple CGM for effortless diabetes management. The low-profile, all-in-one wearable sensor warms up in only 30 minutes, 2x faster than any other CGM on the market.[†] Users will receive real-time glucose readings automatically on their compatible smart device[‡] or Dexcom receiver, no fingersticks[§] required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels with a predictive low alert that can recognize potentially dangerous hypoglycemic incidents before they occur.

Dexcom G7 is the most accurate CGM system¹ for reliable treatment decisions that lead to proven results.³⁻⁷ Dexcom G7 is clinically proven to lower A1C,³⁻⁷ increase time in range,⁴ reduce hyper- and hypoglycemia,^{4,5} increase adherence,⁹ and improve quality of life.¹⁰ Dexcom G7 is the preferred CGM of national payors on the pharmacy benefit. As the most covered CGM brand,⁸ Dexcom requires only one prescription for Dexcom G7 to be sent directly to the pharmacy for a quick, simple start and low out-of-pocket costs with most patients paying \$0 at the pharmacy.^{1*}

Dexcom G7 is an integrated CGM (iCGM) indicated for the widest age range and across diabetes types (type 1, type 2, and gestational diabetes) and treatment types (basal insulin, noninsulin, GLP-1). Dexcom G7 is covered by Medicare for qualifying patients^{11,11} For more information on affordability programs, please visit dexcom.com/savings.

Features & Options

Dexcom G7 features the most accurate CGM powering automated insulin delivery (AID) systems:

- Two times faster warmup than any other CGM.[†]
- Only CGM with share/follow while using an AID system.
- Only CGM with no fingersticks from day one.[§]
- Only CGM with app features that help protect from severe hypoglycemia and diabetic ketoacidosis.
- Smallest CGM sensor currently powering AID systems.
- Over 1 million patient-years on AID systems.¹²

Testimonials

Dexcom G7 is the simple and most affordable CGM:

- 96% of patients say Dexcom G7 is easy to use.¹³
- Nine out of 10 Dexcom users stay on product after one year.¹
- Dexcom is #1 in patient satisfaction,^{14,11} adherence,^{15,#} and retention.^{15,#}
- Dexcom is the preferred CGM of national payors on the pharmacy benefit.
- 90% of commercial patients have coverage at the pharmacy and the majority do not have a manual prior authorization.
- Most Medicare Advantage patients have coverage at the pharmacy.
- Savings programs are available for patients without CGM coverage.

Ordering Information

To order, please contact your pharmacy wholesale partner. Dexcom G7 is available to order from all major wholesalers.

*Individual pricing may vary depending on commercial insurance coverage.

†Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

‡Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility.

§Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

|| Coverage criteria may vary by plan.

¶Based on net promoter score Dexcom 81 vs. Abbott 27 (Medtronic 10).

#Based on use out of 30 days.

1 Dexcom, data on file, 2023. 2 Dexcom, data on file, 2022. 3 Welsh JB, et al. J Diabetes Sci Technol. 2022. Published online June 13, 2022. doi:10.1177/19322968221099879 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 9 Nemlekar PM, et al. Diabetes Ther. Published online January 30, 2024. doi:10.1007/s13300-023-01529-8. 10 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39. 11 Dexcom. Accessed February 16, 2024. <https://investors.dexcom.com/news/news-details/2023/Dexcom-G7-Continuous-Glucose-Monitoring-System-Will-Be-Available-to-Medicare-Beneficiaries-at-Launch/default.aspx>. 12 Dexcom. Accessed February 16, 2024. <https://investors.dexcom.com/news/news-details/2023/Dexcom-G7-the-Smallest-Most-Accurate-Easy-to-Use-CGM-Now-Connects-to-the-Tandem-tslim-X2-Insulin-Pump/default.aspx> 13 Dexcom G7 CGM System User Guide, 2023. 14 IQVIA, February 2022. 15 Seagrove Patient Perspectives 2020.